Tirzepatide 7.5mg
Tirzepatide 7.5mg is a prescriber-directed weight-management medication option. It should be used as part of a broader care plan that includes nutrition, activity, contraindication screening, and monitoring.
Tirzepatide 7.5 mg is a compounded subcutaneous injectable preparation of tirzepatide, a dual GIP and GLP-1 receptor co-agonist. The 7.5 mg dose is an intermediate step in the standard escalation schedule, typically reached after at least 4 weeks at 5 mg, providing ongoing titration flexibility for prescriber-directed glycemic and weight management. Genesis Compounding prepares this as a prescription-only, patient-specific 503A compounded preparation and it is not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Tirzepatide 7.5 mg | Dual GIP/GLP-1 receptor co-agonist providing enhanced glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction for type 2 diabetes and chronic weight management. |
Administered by subcutaneous injection once weekly into the abdomen, thigh, or upper arm. Rotate injection sites each week. Solution should appear clear, colorless to slightly yellow; discard if discolored or particulate matter is present.
Tirzepatide 7.5 mg once weekly is typically used following at least 4 weeks at 5 mg. It may serve as an intermediate maintenance dose or a step toward higher doses (10 mg, 12.5 mg, or 15 mg):
- Titration occurs in 2.5 mg increments no sooner than every 4 weeks
- Maximum dose: 15 mg once weekly (adults)
- All titration decisions are made by the prescribing clinician
- Tirzepatide: Co-agonist at both GIP and GLP-1 receptors. Activation of GLP-1 receptors enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite. Concurrent GIP receptor activation synergistically amplifies insulin secretion and may contribute to adipose tissue lipid metabolism effects. Together, these pathways drive greater glycemic and weight reductions than GLP-1 agonism alone.
Tirzepatide 7.5 mg is used in patients progressing along the standard titration schedule for type 2 diabetes management or chronic weight management. At 7.5 mg, clinically meaningful HbA1c and weight reductions are expected. Monitoring parameters are consistent with all tirzepatide doses.
Contraindications:
- Personal or family history of MTC or MEN 2
- Hypersensitivity to tirzepatide
Warnings & Precautions:
- Thyroid C-cell tumor risk
- Pancreatitis
- Hypoglycemia with insulin or sulfonylureas
- GI adverse effects
- Renal impairment from dehydration
Drug Interactions:
- Insulin/secretagogues: hypoglycemia risk
- Oral medications: altered absorption due to delayed gastric emptying
Common Side Effects: Nausea, vomiting, diarrhea, constipation, decreased appetite, and injection site reactions.
Refrigerate at 2–8°C; protect from light; do not freeze. Use within the beyond-use date specified by Genesis Compounding. Discard if solution is not clear or contains particulates.
Is 7.5 mg a maintenance dose or a titration step?
It can be either. Some patients find 7.5 mg achieves their therapeutic goals, making it a maintenance dose. Others use it as a step toward higher doses (10–15 mg) for greater efficacy.
How is this injected?
Subcutaneous injection once weekly, rotating among abdomen, thigh, and upper arm each dose.
Is this FDA-approved?
Tirzepatide 7.5 mg is commercially available in FDA-approved branded products. This is a 503A compounded preparation by Genesis Compounding and is not FDA-approved as a compounded product.
What GI effects are expected at this dose?
Nausea and GI discomfort may occur, especially if dose was recently escalated. These typically diminish within 4 weeks as the body adjusts to the higher dose.
What labs should be monitored?
HbA1c, fasting glucose, body weight, and renal function (if GI symptoms are significant) should be monitored per your prescriber's schedule.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.